MedTrace Logo

Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

NCT06758947 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-01-06

No results posted yet for this study

Summary

Systemic sclerosis (SSc) is a systemic autoimmune disease with heterogeneous clinical presentation and prognosis. JAK inhibitors reduced cutaneous and pulmonary fibrosis in mice models of SSc. Clinical data regarding the efficacy and safety of JAK inhibitors in SSc patients are scarce

Conditions

  • Interstitial Lung Disease Due to Systemic Disease (Disorder)

Interventions

DRUG

Upadacitinib 15 MG

oral tablet upadacitinib

DEVICE

Cellcept Oral Product

active control group 2000mg MMF daily

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Manal Hassanien, professor · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-15
Primary Completion
2024-06-15
Completion
2024-11-15
FDA Drug
Yes
FDA Device
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06758947 on ClinicalTrials.gov